Clinical trials: HIV Lipodystrophy
HIV
Eplerenone in HIV Associated Abdominal Fat Accumulation
The purpose of this study is to test the effects of a drug, eplerenone, along with lifestyle modification to affect sugar metabolism, body fat distribution, and cardiovascular health in HIV-infected individuals.
- Trial name
- NCT01405456
- Testing
- Eplerenone and lifestyle
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Lipodystrophy, HIV Infection
Metabolic Abnormalities in HIV-infected Persons
The purpose of this study is to examine the relationship between insulin resistance and changes in body fat distribution in HIV-infected persons.
- Trial name
- NCT01612858
- Testing
- Metformin, Pioglitazone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tufts Medical Center
Lipodystrophy, HIV Infections
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
- Trial name
- NCT00608023
- Testing
- Tesamorelin
- Where
- 47 sites in United States, Belgium and 4 more
- Volunteers
- 263 people
- Sponsor
- Theratechnologies
HIV Facial Lipoatrophy
Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy
The purpose of this study is to test the safety of Voluma and see what effects it has on HIV facial lipoatrophy. The hypothesis is that Voluma will be safe, efficacious and positively impact the quality-of-life in the treatment…
- Trial name
- NCT02342223
- Testing
- Voluma
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jared Jagdeo, MD, MS
HIV Infections
HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
This study is being done to better understand why people with HIV who have taken drugs for HIV begin to show abnormal changes in fat loss or fat gain in their bodies. This condition is called lipodystrophy.
- Trial name
- HAL (NCT01023620)
- Testing
- Pioglitazone, Observation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Texas Southwestern Medical Center
HIV Lipodystrophy
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
The purpose of this study is to determine whether patients with HIV lipodystrophy (fat wasting) benefit from taking the combination of two drugs, one insulin sensitizer (either metformin or pioglitazone, both diabetes drugs) and…
- Trial name
- NCT00362440
- Testing
- Leptin, Pioglitazone or metformin
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
HIV Infections, Lipodystrophy
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome…
- Trial name
- NCT00082628
- Testing
- Serostim® 4 mg, Serostim® 2 mg
- Where
- 31 sites in United States, Canada
- Volunteers
- 326 people
- Sponsor
- EMD Serono
HIV Infections, Lipodystrophy
Therapeutic Approaches to HAART-Induced Lipodystrophy
To determine the efficacy and safety of 4 therapeutic interventions on HAART-Induced lipodystrophy. The interventions are: 1) Dietary - the effect of a high carbohydrate vs.a high cis-monounsaturated fatty acid diet.
- Trial name
- NCT00461552
- Testing
- Leptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Texas Southwestern Medical Center
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the…
- Conditions
- HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X
- Trial name
- NCT00130286
- Testing
- Rosiglitazone, Recombinant human growth hormone + rosiglitazone
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Weill Medical College of Cornell University
HIV Infections
Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications
The purpose of this study is to observe the effects of certain anti-HIV medications on mitochondrial activity and fat cell death.
- Trial name
- NCT00433992
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Cardiovascular Disease
Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
We hypothesize that the hearts of HIV+ people with The Metabolic Syndrome use and oxidize fats and sugars inappropriately, and that this may impair the heart's ability to pump blood.
- Conditions
- HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy
- Trial name
- WU197 (NCT00656851)
- Testing
- Pioglitazone, Exercise Training
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infection
A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine
The purpose of this study is to compare the body fat distribution in Human Immunodeficiency Virus-1 (HIV-1) infected patients receiving, since the beginning and for at least two years, an antiretroviral therapy based on efavirenz…
- Trial name
- LYNX (NCT01159743)
- Where
- 26 sites in Spain
- Volunteers
- 346 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections, Type 2 Diabetes
Exercise and Pioglitazone for HIV-Metabolic Syndromes
The purpose is to examine the safety and efficacy of 16wks of pioglitazone (Actos; 30mg/d) with and without aerobic and strength exercise training for reducing glucose intolerance and central adiposity in HIV-infected people.
- Conditions
- HIV Infections, Type 2 Diabetes, Obesity, HIV
- Trial name
- NCT00639457
- Testing
- Pioglitazone, Exercise training
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infection, Mitochondrial Dysfunction
Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
The purposes of this study are to evaluate if switching an antiretroviral medication from efavirenz (EFV) to atazanavir/ ritonavir (ARV/r) will, in a 96-week period, change: 1.
- Trial name
- NCT01194856
- Testing
- Atazanavir/ritonavir, Efavirenz
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The Cleveland Clinic
Cardiovascular Diseases, Heart Diseases
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
This study will evaluate the efficacy of diet and exercise (DE), with and without niacin and fenofibrate, in reducing the cardiovascular risk of patients with HIV lipodystrophy or dyslipidemia.
- Conditions
- Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia
- Trial name
- HeartPositive (NCT00246376)
- Testing
- Diet, Exercise, Niacin
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Baylor College of Medicine
HIV Infections, Lipodystrophy
Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults
HIV lipoatrophy is a condition marked by fat loss; it occurs in many patients taking antiretroviral (ARV) therapy that includes nucleoside reverse transcriptase inhibitors (NRTIs).
- Conditions
- HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT00119379
- Testing
- NucleomaxX, Tenofovir Disoproxil Fumarate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Lipoatrophy
Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy
Lipoatrophy, the loss of body fat from particular areas of the body, is a common side effect of antiretroviral therapy (ART). The purpose of this study was to determine the effectiveness of uridine supplementation in treating HIV…
- Trial name
- NCT00307164
- Testing
- NucleomaxX
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 167 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency
Body Composition and Adipose Tissue in HIV
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity.
- Conditions
- HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
- Trial name
- NCT03226821
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
HIV Lipodystrophy
Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
"HIV lipodystrophy syndrome" (HLS) is characterized by loss of fat in the arms and legs, with increase in fat in the abdomen, and abnormal blood lipid levels.
- Trial name
- NCT01511016
- Testing
- Human recombinant leptin ("metreleptin")
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Baylor College of Medicine
HIV Posterior Cheek Enlargement
HIV Posterior Cheek Enlargement
Altered contour of the lower face is a frequent complication of human immunodeficiency virus (HIV). HIV facial lipoatrophy or loss of facial fat commonly results from antiretroviral therapy.
- Trial name
- NCT01635504
- Testing
- Botulinum toxin A
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- University of British Columbia